(NASDAQ:IMMX) IMMIX BIOPHARM INC. share are rallying this morning in pre-market up to $2.66 a share. Shares are up more than 43% on more than 21,000 trades one hour before the open.
LOS ANGELES, May 20, 2022 (GLOBE NEWSWIRE) — Immix Biopharma,Inc. (Nasdaq:IMMX) (ImmixBio, Company, We or Us),a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)targeting oncology and immuno-dysregulated diseases, today announced positive interim study data showing that after one cycle of treatment, ImmixBios lead candidate IMX-110 produced 75% survival vs. 0% survival for Trabectedin (sold as YONDELIS by Janssen, a Johnson & Johnson Company, a U.S. FDA approved drug) in a connective tissue cancer Soft Tissue Sarcoma (STS) mice study. In this study, IMX-110 was compared against approved drugs used to treat STS. Trabectedin was dosed according to Meco et. al., 2003 (trabectedin monotherapy treatment arm) and IMX-110 was administered at 2.0 mg/kg.
We are excited to see continued evidence of IMX-110 anti-tumor activity versus approved therapies, said Ilya Rachman, MD PhD, CEO of ImmixBio. We believe this is a preview of anti-tumor activity to be demonstrated in our 2 clinical trials to be kicked-off in 2022: IMX-110 monotherapy, and IMX-110 in combination with anti-PD-1 tislelizumab.
About Immix Biopharma, Inc.
Immix Biopharma, Inc. (ImmixBio) (Nasdaq:IMMX) is a clinical-stage biopharmaceutical company pioneering a novel class of Tissue-Specific Therapeutics (TSTx)targeting oncology and immuno-dysregulated diseases. Our lead asset IMX-110, currently in Phase 1b/2a clinical trials, holds orphan drug designation (ODD) by the FDA for soft tissue sarcoma, and has received Rare Pediatric Disease Designation (RPDD) for the treatment of rhabdomyosarcoma, a life-threatening form of cancer in children. RPPD qualifies ImmixBio to receive fast track review and a priority review voucher (PRV) at the time of marketing approval of IMX-110. Our proprietary SMARxT Tissue-SpecificPlatform produces drug candidates that circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all 3 components of the tumor micro-environment (TME). We believe ImmixBios TME Normalizationtechnology severs the lifelines between the tumor and its metabolic and structural support. Learn more at www.immixbio.com.